In the study of Holst et al. [7] ESR1 amplification was associated with longer OS of tamoxifen-treated patients; and Tomita et al. [6] showed longer DFS in a consecutive group of breast cancer patients. The gene discussed is ESR1; the disease is breast carcinoma.